Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19.

Abstract

Aim: The authors studied the role of soluble ST2 (sST2) in COVID-19 and its relationship with inflammatory status and disease severity. Materials & methods: Serum levels of sST2 and interleukin (IL)-33, C-reactive protein (CRP), serum amyloid protein (SAA), IL-6 and procalcitonin (PCT), and T lymphocyte subsets from 80 subjects diagnosed with COVID-19 including 36 mild, 41 severe and three asymptomatic cases were tested. Results: Serum sST2 levels were significantly increased in COVID-19 patients, which were positively correlated with CRP, but negatively correlated with CD4+ and CD8+ T lymphocyte counts. Serum sST2 levels in nonsurviving severe cases were persistently high during disease progression. Conclusion: Serum sST2 level test is helpful for reflecting inflammatory status and illness severity of COVID-19.

• Authors: Zhikun Zeng, Xiao-Yue Hong, Yunhui Li, Wei Chen, Guangming Ye, Yirong Li, Yi Luo
• Journal: Biomarkers in medicine (Biomark Med) Vol. 14 Issue 17 Pg. 1619-1629 (12 2020) ISSN: 1752-0371 [Electronic] England
• PMID: 33336592 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Biomarkers
• IL1RL1 protein, human
• Interleukin-1 Receptor-Like 1 Protein
• Procalcitonin
• Serum Amyloid A Protein
• C-Reactive Protein

Topics

• Adult
• Aged
• Aged, 80 and over
• Biomarkers (blood)
• C-Reactive Protein (metabolism)
• CD4-Positive T-Lymphocytes (metabolism)
• CD8-Positive T-Lymphocytes (metabolism)
• COVID-19 (blood)
• Female
• Humans
• Interleukin-1 Receptor-Like 1 Protein (blood)
• Male
• Middle Aged
• Procalcitonin (blood)
• SARS-CoV-2 (metabolism)
• Serum Amyloid A Protein (metabolism)
• Severity of Illness Index